<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041751</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0498</org_study_id>
    <secondary_id>NCI-2020-13900</secondary_id>
    <secondary_id>2020-0498</secondary_id>
    <nct_id>NCT05041751</nct_id>
  </id_info>
  <brief_title>Myofascial Release or Trigger Point Injections for the Reduction of Post-Mastectomy Pain Syndrome</brief_title>
  <official_title>A Pilot Study Assessing the Benefits of Fascial Freedom for the Win (MFR Versus TPI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies the effect of myofascial release in decreasing post-mastectomy&#xD;
      pain compared to standard of care trigger point injections in patients with post-mastectomy&#xD;
      pain syndrome. Patients who have mastectomies often experience pain that does not go away&#xD;
      after time. This is known as post-mastectomy pain syndrome. Myofascial release is a form of&#xD;
      physical therapy in which pressure is applied to the affected areas. Myofascial release may&#xD;
      be an effective way of decreasing pain in patients with post-mastectomy pain syndrome without&#xD;
      the use of medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the change in pain score using the Numerical Rating Scale for pain on an&#xD;
      11-point scale (0-none to 10-worst) from implementation of myofascial release (MFR) versus&#xD;
      trigger point injections (TPI) in the treatment of myofascial trigger points (MTP) as&#xD;
      noninvasive therapies for post mastectomy pain syndrome (PMPS).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the change in medications, particularly opiate medications in the treatment of&#xD;
      post mastectomy pain.&#xD;
&#xD;
      II. To evaluate a patient's satisfaction with therapy or treatment throughout the course of&#xD;
      the study at each consecutive encounter or follow up.&#xD;
&#xD;
      III. To evaluate a patient's range of motion with therapy or treatment beginning at time of&#xD;
      screening and until the end of the study.&#xD;
&#xD;
      IV. To evaluate a patient's degree of lymphedema both subjectively and objectively in the&#xD;
      affected extremity(ies) unilateral to the site(s) of mastectomy in response to the various&#xD;
      forms of treatment throughout the study.&#xD;
&#xD;
      V. To evaluate quality of life measure changes with treatments used throughout the study.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive standard of care trigger point injections at baseline.&#xD;
&#xD;
      ARM II: Patients perform myofascial release for 10 minutes each day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain response</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Defined by score differences (using the pain numerical rating scale). an 11-point scale (0-none to 10-worst) Pain responders will be defined as patients demonstrating an equal or lower pain score relative to baseline. The 2-week post-treatment assessment will be used to assess the primary endpoint.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (trigger point injections)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard of care trigger point injections at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (myofascial release)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients perform myofascial release for 10 minutes each day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Acupuncture Point Injection</intervention_name>
    <description>Receive trigger point injections</description>
    <arm_group_label>Arm I (trigger point injections)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Massage Therapy</intervention_name>
    <description>Perform myofascial release</description>
    <arm_group_label>Arm II (myofascial release)</arm_group_label>
    <other_name>Massage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (trigger point injections)</arm_group_label>
    <arm_group_label>Arm II (myofascial release)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (trigger point injections)</arm_group_label>
    <arm_group_label>Arm II (myofascial release)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic post-mastectomy pain syndrome (&gt;= 3 months)&#xD;
&#xD;
          -  Able to perform MFR techniques and follow basic instructions&#xD;
&#xD;
          -  &gt;= 18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current chemotherapy&#xD;
&#xD;
          -  Pending surgery during treatment&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Active debilitating disease&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Other chronic pain diagnosis beside PMPS&#xD;
&#xD;
          -  Untreated psychiatric diagnosis (not receptive to taking precautions and interventions&#xD;
             by treating psychiatrist/psychologist/physician i.e. taking necessary medications)&#xD;
&#xD;
          -  Morbid obesity (body mass index [BMI] &gt; 40)&#xD;
&#xD;
          -  Allergy history of bupivacaine and/or lidocaine&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Le-Short</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christina Le-Short</last_name>
    <phone>713-792-9669</phone>
    <email>cle2@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Christina Le-Short</last_name>
      <phone>713-792-9669</phone>
    </contact>
    <investigator>
      <last_name>Christina Le-Short</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

